Glaukos Corporation
GKOSHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeGlaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and. At a $9.21B market cap, Glaukos Corporation ranks as a mid-cap company within healthcare. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Market Cap
$9.21B
Beta
0.75
P/E (TTM)
—
P/E (Fwd)
369.94
EPS (TTM)
$-3.32
EPS (Fwd)
$0.42
ROE
-26.4%
ROA
-5.8%
Cash
$276.7M
Total Debt
$105.9M
Free CF
$6.1M
52W Change
60.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $276.7M in cash comfortably exceeding the $105.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $6.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -26.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $282.9M (2022) to $507.4M (2025), reflecting a 79% increase over the period.
With cash comfortably exceeding debt, GKOS has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing GKOS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.